コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 for type 2 diabetes should be established by cost-effectiveness analysis.
2 servative assumptions, the authors performed cost-effectiveness analysis.
3 oring) were derived from data in the GUSTO-1 cost-effectiveness analysis.
4 ths after hospitalization and (2) a lifetime cost-effectiveness analysis.
5 cal technologies, with a particular focus on cost-effectiveness analysis.
6 er importance on equity than is reflected by cost-effectiveness analysis.
7 cost-utility analysis and trial efficacy for cost-effectiveness analysis.
8 uation was a randomized clinical trial-based cost-effectiveness analysis.
9 l costs of the 2 programs were collected for cost-effectiveness analysis.
10 -effective in both cost-utility analysis and cost-effectiveness analysis.
11 ge decrease in risk of eczema in the primary cost-effectiveness analysis.
12 ndividuals and the time horizon used for the cost-effectiveness analysis.
13 These findings may be informed by a cost-effectiveness analysis.
14 on in England, although we did not include a cost-effectiveness analysis.
15 species spread risk assessment with a policy cost-effectiveness analysis.
16 sis of the effect of multiple-dose MDA and a cost-effectiveness analysis.
17 We present a five-country cost-effectiveness analysis.
18 Model-based cost-effectiveness analysis.
19 We compared alternatives using incremental cost-effectiveness analysis.
20 This study omitted cost-effectiveness analysis.
21 rmatics, 3) databases, 4) biomarkers, and 5) cost-effectiveness analysis.
22 randomised controlled trial with a parallel cost-effectiveness analysis.
23 r error avoided was estimated by incremental cost-effectiveness analysis.
24 We did a Markov model-based probabilistic cost-effectiveness analysis.
25 es a conceptual link with the denominator of cost-effectiveness analysis.
26 have implications for decision analysis and cost-effectiveness analysis.
27 DESIGN, SETTING, AND PARTICIPANTS: In this cost-effectiveness analysis, a decision-analytic Markov
29 's recommendations define a "reference case" cost-effectiveness analysis, a standard set of methods t
33 to make economic evaluation methods (such as cost-effectiveness analysis) an effective component of v
34 ion analysis; (2) cost-benefit analysis; (3) cost-effectiveness analysis and (4) cost-utility analysi
35 reviewed the current status of the field of cost-effectiveness analysis and developed a new set of r
37 ion analysis, (2) cost-benefit analysis, (3) cost-effectiveness analysis, and (4) cost-utility analys
38 96, researchers have advanced the methods of cost-effectiveness analysis, and policy makers have expe
39 , budget impact, and sustainability into the cost-effectiveness analysis are needed to reach this goa
40 s the rationale, terminology, and methods of cost-effectiveness analysis as applied to radiology.
43 to be based not only on outcome evidence and cost-effectiveness analysis, but also on safety consider
44 care, abandoning the formulaic pretenses of cost-effectiveness analysis, but with a commitment to re
45 ften being more expensive at the outset, and cost-effectiveness analysis can aid patients and clinici
48 Simulation models that support decision and cost-effectiveness analysis can further the goals of evi
50 rched studies in PubMed, Embase, Scopus, and Cost Effectiveness Analysis (CEA) registry, from incepti
51 PARTICIPANTS: This economic evaluation was a cost-effectiveness analysis (CEA) and budget impact anal
52 olicy statement arguing for the inclusion of cost-effectiveness analysis (CEA) and value assessments
54 rices with clinical benefit, and traditional cost-effectiveness analysis (CEA) faces political obstac
55 tion of CPA and SC were determined using the cost-effectiveness analysis (CEA) in the Malaysian healt
56 impacts across 18 midpoint indicators, while cost-effectiveness analysis (CEA) incorporated cost and
67 nd eliminated wait time (EWT), and perform a cost-effectiveness analysis comparing RWT and EWT with c
68 ts were combined with clinical outcomes in a cost-effectiveness analysis comparing the intervention w
74 were assessed based on the inclusion of key cost-effectiveness analysis elements and global ratings
79 ample, decision analysis and cost utility or cost effectiveness analysis for health technology assess
84 the Ministry of Health and Population, and a cost-effectiveness analysis, from a societal perspective
89 Guidelines based on systematic reviews and a cost-effectiveness analysis have suggested that it is wo
90 uld undergo imaging and, in combination with cost-effectiveness analysis, how imaging should be perfo
91 ragmatic randomized trial with an integrated cost-effectiveness analysis in 56 hospitals in England.
92 clinical specialties necessitate an updated cost-effectiveness analysis in a centralized, largely go
93 lower total positive rates yield a promising cost-effectiveness analysis in favor of universal ECG sc
95 to our knowledge there has been no previous cost-effectiveness analysis in pediatric IF including IR
96 d febrile neutropenia cost information and a cost-effectiveness analysis in the adjuvant breast cance
107 on to providing treatment recommendations, a cost-effectiveness analysis is provided that might help
108 hen there are budget limitations, the use of cost-effectiveness analysis leads to health care policie
110 ethods in cost-utility analysis (incremental cost-effectiveness analysis) might potentially bias agai
114 economic evaluation study was a within-trial cost-effectiveness analysis of a stepped-wedge cluster r
116 rpose of this investigation was to perform a cost-effectiveness analysis of adjunctive oral and intra
118 mplementation in South Africa we performed a cost-effectiveness analysis of alternative preventive st
120 we addressed this gap by including BM in the cost-effectiveness analysis of atezolizumab for EX-SCLC.
121 odel based on results from BOSS to conduct a cost-effectiveness analysis of costs and quality-adjuste
126 US adults (aged 15-65 years) and conducted a cost-effectiveness analysis of improvements along the HI
127 ted population, we conducted a comprehensive cost-effectiveness analysis of iptacopan monotherapy in
129 s the importance of performing more accurate cost-effectiveness analysis of novel adjuvant therapies
130 economic evaluation conducted a model-based cost-effectiveness analysis of PEH with OUD in the US.
131 of treatment provide information for future cost-effectiveness analysis of potential innovative inte
132 CIPANTS: This economic evaluation involved a cost-effectiveness analysis of results from a randomized
133 for socially assistive robots can be made, a cost-effectiveness analysis of socially assistive robots
141 ted thromboses, but confirmatory studies and cost-effectiveness analysis of this approach are needed.
143 y heart disease with lipid lowering therapy, cost effectiveness analysis offers an important tool to
144 m this review could be used to inform future cost-effectiveness analysis on the impact of LTBI screen
145 tiveness ratio" OR "economic evaluation" OR "cost effectiveness analysis" OR "cost utility analysis"
146 assessed HIV outcomes in 2030 and conducted cost-effectiveness analysis over a 50 year time horizon.
152 gression is a promising method to synthesise cost-effectiveness analysis results and transfer them ac
155 familiar with the concepts and procedures of cost-effectiveness analysis so they can properly evaluat
156 eness analysis so they can properly evaluate cost-effectiveness analysis studies and be more knowledg
157 nt colonic obstruction has been supported by cost-effectiveness analysis studies and several pooled a
159 en unselected for hormone receptor status, a cost-effectiveness analysis suggests that this intervent
163 For the purposes of clinical prognosis and cost-effectiveness analysis, the long-term survival of p
165 s in more detail the elements contained in a cost-effectiveness analysis, the preferred approach to p
176 eatment trials are warranted, we conducted a cost-effectiveness analysis to estimate the costs and be
180 rd trimesters, but noted the importance of a cost-effectiveness analysis to lend support to the decis
182 This article demonstrates the usefulness of cost-effectiveness analysis to support these decisions.
183 e, randomised controlled trial with parallel cost-effectiveness analysis undertaken in England, 701 a
187 GN, SETTING, AND PARTICIPANTS: A comparative cost-effectiveness analysis using 4 independently develo
191 nts with atrial fibrillation, we performed a cost-effectiveness analysis using patient-level data fro
203 In this economic evaluation, an incremental cost-effectiveness analysis was performed from the socie
205 lled trial with two open parallel arms and a cost-effectiveness analysis was performed in 12 tertiary
212 DESIGN, SETTING, AND PARTICIPANTS: This cost-effectiveness analysis was performed using data fro
213 SIGN, SETTING, AND PARTICIPANTS: An in-trial cost-effectiveness analysis was performed using patient-
219 omic evaluation, which used a distributional cost-effectiveness analysis, was conducted from June 16,
226 125 [29.2%] usual care) were included in the cost-effectiveness analysis (which included 120 patients
227 " Second, it describes decision analysis and cost-effectiveness analysis, which are quantitative mode
228 narrowly focused on clinical outcomes using cost-effectiveness analysis, which may be of little rele